CIK 0001787306
- Large accelerated filer
Arcutis Biotherapeutics, Inc.
Sign in to watch- Ticker
- ARQT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 812974255
- Phone
- +1 805-418-5006
- Business address
- 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE, CA, 91361
- Former names
- Arcutis, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,253,826
- in 9 filings, $2.1M under 10b5-1 plans
Net −$3,253,826. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-04 | Watanabe Todd Franklin | Sale 10b5-1 | −14,903 | $11.12 | $166K | 874,533 |
| 2024-03-04 | Moore Matthew Richard SVP and Chief Business Officer | Sale 10b5-1 | −3,468 | $11.12 | $39K | 146,020 |
| 2024-03-04 | Heron Patrick J Director | Purchase | +21,052 | $9.50 | $200K | 8,785,284 |
| 2024-02-28 | Watanabe Todd Franklin | Sale 10b5-1 | −2,465 | $10.60 | $26K | 889,436 |
| 2024-02-13 | Moore Matthew Richard SVP and Chief Business Officer | Grant or award | +26,666 | 81,256 | ||
| 2024-02-13 | Moore Matthew Richard SVP and Chief Business Officer | Grant or award | +26,666 | 107,922 | ||
| 2024-02-13 | Moore Matthew Richard SVP and Chief Business Officer | Grant or award | +17,650 | 125,572 | ||
| 2024-02-13 | Moore Matthew Richard SVP and Chief Business Officer | Grant or award | +19,750 | 145,322 | ||
| 2024-02-13 | Moore Matthew Richard SVP and Chief Business Officer | Grant or award | +4,166 | 149,488 | ||
| 2024-02-13 | Moore Matthew Richard SVP and Chief Business Officer | Returned to the company · Stock Option (Right to Buy) | −80,000 | 0 | ||
| 2024-02-13 | Moore Matthew Richard SVP and Chief Business Officer | Returned to the company · Stock Option (Right to Buy) | −80,000 | 0 | ||
| 2024-02-13 | Moore Matthew Richard SVP and Chief Business Officer | Returned to the company · Stock Option (Right to Buy) | −35,300 | 0 | ||
| 2024-02-13 | Moore Matthew Richard SVP and Chief Business Officer | Returned to the company · Stock Option (Right to Buy) | −39,500 | 0 | ||
| 2024-02-13 | Moore Matthew Richard SVP and Chief Business Officer | Returned to the company · Stock Option (Right to Buy) | −12,500 | 0 | ||
| 2024-02-13 | Burnett Patrick | Grant or award | +128,000 | 213,032 | ||
| 2024-02-13 | Burnett Patrick | Grant or award | +9,600 | 222,632 | ||
| 2024-02-13 | Burnett Patrick | Grant or award | +23,550 | 246,182 | ||
| 2024-02-13 | Burnett Patrick | Grant or award | +27,900 | 274,082 | ||
| 2024-02-13 | Burnett Patrick | Returned to the company · Stock Option (right to buy) | −320,000 | 0 | ||
| 2024-02-13 | Burnett Patrick | Returned to the company · Stock Option (right to buy) | −28,800 | 0 |
Page 20 of 35 · 689 trades